Prime Medicine Inc (PRME)
7.04
+0.28
(+4.14%)
USD |
NASDAQ |
May 16, 16:00
7.02
-0.02
(-0.28%)
After-Hours: 20:00
Prime Medicine Cash from Financing (Quarterly): 157.33M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 157.33M |
| December 31, 2023 | 0.194M |
| September 30, 2023 | 0.318M |
| June 30, 2023 | 0.075M |
| March 31, 2023 | 0.068M |
| Date | Value |
|---|---|
| December 31, 2022 | 184.07M |
| September 30, 2022 | -0.683M |
| June 30, 2022 | -0.624M |
| March 31, 2022 | -1.272M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.272M
Minimum
Mar 2022
184.07M
Maximum
Dec 2022
37.72M
Average
0.075M
Median
Jun 2023
Cash from Financing (Quarterly) Benchmarks
| 10x Genomics Inc | 1.638M |
| Verve Therapeutics Inc | 22.73M |
| Ionis Pharmaceuticals Inc | 23.57M |
| Solid Biosciences Inc | 0.505M |
| Beam Therapeutics Inc | 2.897M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -67.71M |
| Cash from Investing (Quarterly) | -37.03M |
| Free Cash Flow | -200.61M |
| Free Cash Flow Per Share (Quarterly) | -0.6704 |
| Free Cash Flow to Firm (Quarterly) | -70.03M |
| Free Cash Flow Yield | -30.05% |